Do analysts recommend QNTM or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, QNTM or TCRT?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is QNTM or TCRT more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts prefer TIL or QNTM?

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 743.99%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, TIL or QNTM?

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is TIL or QNTM more profitable?

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Quantum Biopharma N/A -941.54% -224.41%

Do analysts rate QNTM or ATHE?

Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 158.45%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation and earnings, QNTM or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is QNTM or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Alterity Therapeutics N/A N/A N/A

Does the media favor QNTM or ATHE?

In the previous week, Quantum Biopharma and Quantum Biopharma both had 3 articles in the media. Quantum Biopharma's average media sentiment score of 0.47 beat Alterity Therapeutics' score of 0.29 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate IZTC or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, IZTC or QNTM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is IZTC or QNTM more profitable?

Invizyne Technologies' return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Quantum Biopharma N/A -941.54% -224.41%

Does the media prefer IZTC or QNTM?

In the previous week, Quantum Biopharma had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Invizyne Technologies. Quantum Biopharma's average media sentiment score of 0.47 beat Invizyne Technologies' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer QNTM or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 935.03%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is QNTM or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Mereo BioPharma Group N/A -81.28% -70.45%

Quantum Biopharma (QNTM) Competitors

$3.49 -0.04 (-1.13%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$3.38 -0.12 (-3.30%)

As of 07/14/2026 07:41 PM Eastern

Compare

QNTM vs. TCRT, TIL, ATHE, IZTC, and MREO

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Alaunos Therapeutics (TCRT), Instil Bio (TIL), Alterity Therapeutics (ATHE), Invizyne Technologies (IZTC), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.

How does Quantum Biopharma compare to Alaunos Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

In the previous week, Quantum Biopharma had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.47 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Alaunos Therapeutics	Very Positive

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Quantum Biopharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market.

Summary

Alaunos Therapeutics beats Quantum Biopharma on 7 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Quantum Biopharma had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.47 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Quantum Biopharma	Neutral

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Quantum Biopharma	N/A	-941.54%	-224.41%

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 743.99%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Instil Bio has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Summary

Instil Bio beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Alterity Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Alterity Therapeutics' return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Alterity Therapeutics	N/A	N/A	N/A

Quantum Biopharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Quantum Biopharma and Quantum Biopharma both had 3 articles in the media. Quantum Biopharma's average media sentiment score of 0.47 beat Alterity Therapeutics' score of 0.29 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 158.45%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Alterity Therapeutics beats Quantum Biopharma on 8 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

In the previous week, Quantum Biopharma had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Invizyne Technologies. Quantum Biopharma's average media sentiment score of 0.47 beat Invizyne Technologies' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invizyne Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Invizyne Technologies' return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Quantum Biopharma	N/A	-941.54%	-224.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Quantum Biopharma beats Invizyne Technologies on 5 of the 7 factors compared between the two stocks.

How does Quantum Biopharma compare to Mereo BioPharma Group?

Quantum Biopharma (NASDAQ:QNTM) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Quantum Biopharma has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Mereo BioPharma Group	$500K	100.24	-$41.88M	-$0.05	N/A

Mereo BioPharma Group's return on equity of -81.28% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Quantum Biopharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Quantum Biopharma had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Quantum Biopharma and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.47 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 935.03%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Mereo BioPharma Group beats Quantum Biopharma on 9 of the 14 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.47M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.42	20.98	27.01	24.38
Price / Sales	N/A	311.10	519.43	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.60	8.54	10.80	6.33
Net Income	-$26.17M	$23.83M	$3.59B	$331.02M
7 Day Performance	6.73%	-2.77%	-1.47%	-0.33%
1 Month Performance	-5.68%	5.85%	2.78%	-1.29%
1 Year Performance	-81.93%	52.15%	28.50%	21.30%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.1586 of 5 stars	$3.49 -1.1%	N/A	-83.4%	$13.47M	N/A	N/A	N/A
TCRT Alaunos Therapeutics	0.5743 of 5 stars	$2.04 -5.1%	N/A	-47.8%	$52.51M	N/A	N/A	40	Positive News
TIL Instil Bio	1.6943 of 5 stars	$7.75 +0.4%	$66.00 +751.6%	-68.1%	$52.36M	N/A	N/A	410
ATHE Alterity Therapeutics	3.5411 of 5 stars	$5.49 -6.8%	$13.00 +136.8%	+8.6%	$52.23M	N/A	N/A	10	Positive News Gap Up
IZTC Invizyne Technologies	N/A	$8.14 -4.0%	N/A	-35.1%	$50.89M	N/A	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, TIL, ATHE, IZTC, and MREO

How does Quantum Biopharma compare to Alaunos Therapeutics?

Summary

How does Quantum Biopharma compare to Instil Bio?

Summary

How does Quantum Biopharma compare to Alterity Therapeutics?

Summary

How does Quantum Biopharma compare to Invizyne Technologies?

Summary

How does Quantum Biopharma compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, TIL, ATHE, IZTC, and MREO

How does Quantum Biopharma compare to Alaunos Therapeutics?

Do institutionals and insiders believe in QNTM or TCRT?

Do analysts recommend QNTM or TCRT?

Which has higher earnings and valuation, QNTM or TCRT?

Does the media refer more to QNTM or TCRT?

Is QNTM or TCRT more profitable?

Which has more volatility & risk, QNTM or TCRT?

Summary

How does Quantum Biopharma compare to Instil Bio?

Does the media refer more to TIL or QNTM?

Is TIL or QNTM more profitable?

Do analysts prefer TIL or QNTM?

Do insiders & institutionals believe in TIL or QNTM?

Which has better valuation and earnings, TIL or QNTM?

Which has more volatility and risk, TIL or QNTM?

Summary

How does Quantum Biopharma compare to Alterity Therapeutics?

Is QNTM or ATHE more profitable?

Which has more risk and volatility, QNTM or ATHE?

Do insiders & institutionals believe in QNTM or ATHE?

Does the media favor QNTM or ATHE?

Which has stronger valuation and earnings, QNTM or ATHE?

Do analysts rate QNTM or ATHE?

Summary

How does Quantum Biopharma compare to Invizyne Technologies?

Does the media prefer IZTC or QNTM?

Which has higher earnings & valuation, IZTC or QNTM?

Do institutionals and insiders hold more shares of IZTC or QNTM?

Is IZTC or QNTM more profitable?

Do analysts rate IZTC or QNTM?

Summary

How does Quantum Biopharma compare to Mereo BioPharma Group?

Which has higher valuation & earnings, QNTM or MREO?

Is QNTM or MREO more profitable?

Which has more risk and volatility, QNTM or MREO?

Does the media prefer QNTM or MREO?

Do analysts prefer QNTM or MREO?

Do institutionals & insiders have more ownership in QNTM or MREO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools